1 reply to this topic

[valiantchong]

Hi,

I understand the chances of progress for patients who achived CMR is about 1-2% per year base on IRIS trial. I was wondering why is that so ?

Is it because of non-compliances to drug daily consumption ? What is the actual data ?

[Trey]

Those who achieve 3 log reduction (MMR) or better (CMR) within 18 months have only a very, very small chance of loss of response over the long term.

Regarding the IRIS Trial (the first large scale Gleevec trial), it is NOT progression of those who reached CMR, but rather out of the entire IRIS Trial population, some of whom never achieved a very deep response.  Also, year 7 progression was much higher than the previous 3 years, so year 7 data seems to be a statistical anomoly since during the previous 2 years the progression rate was less than 1%.

Also remember that the IRIS Trial included quite a few patients who had advanced stage disease.  The probability of advancement is somewhat higher in that population, but still minimal after 4 years.  Overall, if a person gets through the first 2 years or so without progression, the rates drop quickly after that.

And this entire discussion assumes only Gleevec, not any second line TKI drugs.

http://www.gleevec.c...ssion-rates.jsp